Bank of America
XFOR icon

Bank of America’s X4 Pharmaceuticals XFOR Stock Holding History

Bank of America’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$622K Buy
150,676
+114,915
+321% +$430K ﹤0.01% 4780
2025
Q4 		$143K Buy
35,761
+16,457
+85% +$59.8K ﹤0.01% 5493
2025
Q3 		$66K Sell
19,304
-61,012
-76% -$157K ﹤0.01% 6759
2025
Q2 		$153K Buy
80,316
+77,738
+3,015% +$318K ﹤0.01% 6313
2025
Q1 		$18.3K Sell
2,578
-1,872
-42% -$25.8K ﹤0.01% 6993
2024
Q4 		$97.9K Buy
4,450
+749
+20% +$11.9K ﹤0.01% 6414
2024
Q3 		$74.3K Buy
3,701
+669
+22% +$14K ﹤0.01% 6442
2024
Q2 		$52.8K Sell
3,032
-392
-11% -$12.8K ﹤0.01% 6499
2024
Q1 		$143K Sell
3,424
-3,672
-52% -$102K ﹤0.01% 6066
2023
Q4 		$178K Sell
7,096
-5,344
-43% -$130K ﹤0.01% 6124
2023
Q3 		$407K Buy
12,440
+10,945
+732% +$477K ﹤0.01% 5452
2023
Q2 		$87K Buy
+1,495
New +$76.8K ﹤0.01% 6257
2023
Q1 		– Sell
-9
Closed -$270 – 8323
2022
Q4 		$270 Buy
+9
New +$426 ﹤0.01% 7498
2022
Q3 		– Hold
0
– – – 8235
2022
Q2 		– Sell
-208
Closed -$7.91K – 8430
2022
Q1 		$11K Sell
208
-106
-34% -$6.08K ﹤0.01% 7719
2021
Q4 		$22K Sell
314
-259
-45% -$32.8K ﹤0.01% 7489
2021
Q3 		$91K Sell
573
-178
-24% -$29.3K ﹤0.01% 6771
2021
Q2 		$147K Sell
751
-306
-29% -$76.9K ﹤0.01% 6289
2021
Q1 		$273K Buy
1,057
+402
+61% +$106K ﹤0.01% 5810
2020
Q4 		$126K Buy
655
+131
+25% +$25.7K ﹤0.01% 5861
2020
Q3 		$106K Sell
524
-48
-8% -$11.5K ﹤0.01% 5676
2020
Q2 		$160K Buy
572
+367
+179% +$100K ﹤0.01% 5398
2020
Q1 		$61K Sell
205
-5
-2% -$1.42K ﹤0.01% 5785
2019
Q4 		$68K Buy
210
+7
+3% +$2.51K ﹤0.01% 6157
2019
Q3 		$78K Buy
203
+73
+56% +$28.9K ﹤0.01% 6159
2019
Q2 		$59K Buy
130
+59
+83% +$30K ﹤0.01% 6234
2019
Q1 		$37K Buy
71
+53
+294% +$29.3K ﹤0.01% 6308
2018
Q4 		$7K Buy
18
+11
+157% +$4.2K ﹤0.01% 6713
2018
Q3 		$2K Buy
7
+2
+40% +$848 ﹤0.01% 7044
2018
Q2 		$3K Buy
5
+3
+150% +$9.82K ﹤0.01% 6877
2018
Q1 		$8K Buy
+2
New +$5.82K ﹤0.01% 6677

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Bank of America's XFOR Position: Q1 2026 in Review

Bank of America increased its X4 Pharmaceuticals (XFOR) stake by 321% in Q1 2026, buying an estimated $430K and bringing the position to 150,676 shares worth $622K. The position accounts for ﹤0.01% of the portfolio, ranked #4780.

Bank of America first reported a position in XFOR in Q1 2018 and has held it in 30 quarters since. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Bank of America held 150,676 shares of X4 Pharmaceuticals worth $622K as of Q1 2026.
  • Bank of America bought 114,915 X4 Pharmaceuticals shares in Q1 2026, an estimated $430K.
  • X4 Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4780 holding.
  • Bank of America first reported a position in X4 Pharmaceuticals in Q1 2018 and has held it in 30 quarters since.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.